18 January 2023 - Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients

Merck has announced that – after a resubmission to SMC – Tepmetko has now been recommended for use through NHS Scotland. The alteration was made following an initial decision by the SMC in June 2022 not to recommend the treatment.

Read Pharma Times article